Is ritexitinib available in the country? How much does it cost per box?

Ritlecitinib (Ritlecitinib) was developed by Pfizer, a world-renowned pharmaceutical company. It is a new type of oral kinase inhibitor. This drug has a unique mechanism of action in that it works primarily by inhibiting tyrosine kinases in the Janus kinase 3 (JAK3) and hepatocellular carcinoma (TEC) kinase families. At the cellular level, ritexitinib can effectively inhibit JAK3-dependent receptor-mediated cytokine-induced STAT phosphorylation, thereby regulating immune receptor signaling and achieving therapeutic purposes.

Its best-known use is in the treatment of alopecia areata, an autoimmune hair loss disease. Traditional treatment methods are mostly oral or topical hormones, but their effects are limited. The emergence of ritexitinib provides a new solution to this problem. Especially in adolescent patients with severe alopecia areata, the drug has shown significant therapeutic effects. According to clinical trial data, approximately 14% to 30% of patients treated with ritixitinib were able to achieve 80% hair regrowth.

In addition to alopecia areata, ritixitinib has shown promise in the treatment of vitiligo, ulcerative colitis and Crohn's disease, among other diseases. This makes it a drug with broad application prospects.

In terms of use, the recommended dosage of ritixitinib is 50 mg once a day. It can be taken with a meal or alone. But it's worth noting that it's not without side effects. Patients may face increased risks of infection, thrombosis and other problems during use, so they need to be used with caution under the guidance of a doctor.

Ritexitinib, a new drug approved by the US FDA in June 2023, sells for up to US$4,000 per box overseas (equivalent to approximately RMB 28,000). In China, the price of this drug is about 3,200 yuan, and each box contains 30 tablets of 50mg. However, a more economical option has emerged in the overseas market, that is, the imitation version produced by Lucius in Laos, which sells for less than 2,000 yuan per box (50 mg 28 tablets).

In summary, ritexitinib, as a new kinase inhibitor, provides a new treatment option for a variety of refractory diseases. However, like any other drug, its use requires weighing efficacy against potential risks. If you have any questions about ritexitinib or need further information, you can seek help from professional overseas medical consultants.